Abstract

Breast tumor morphological and vascular characteristics can be changed during neoadjuvant chemotherapy (NACT). The early changes in tumor heterogeneity can be quantitatively modeled by longitudinal dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), which is useful in predicting responses to NACT in breast cancer. In this retrospective analysis, 114 female patients with unilateral unifocal primary breast cancer who received NACT were included in a development (n = 61) dataset and a testing dataset (n = 53). DCE-MRI was performed for each patient before and after treatment (two cycles of NACT) to generate baseline and early follow-up images, respectively. Feature-level changes (delta) of the entire tumor were evaluated by calculating the relative net feature change (deltaRAD) between baseline and follow-up images. The voxel-level change inside the tumor was evaluated, which yielded a Jacobian map by registering the follow-up image to the baseline image. Clinical information and the radiomic features were fused to enhance the predictive performance. The area under the curve (AUC) values were assessed to evaluate the prediction performance. Predictive models using radiomics based on pre- and post-treatment images, Jacobian maps and deltaRAD showed AUC values of 0.568, 0.767, 0.630 and 0.726, respectively. When features from these images were fused, the predictive model generated an AUC value of 0.771. After adding the molecular subtype information in the fused model, the performance was increased to an AUC of 0.809 (sensitivity of 0.826 and specificity of 0.800), which is significantly higher than that of the baseline imaging- and Jacobian map-based predictive models (p = 0.028 and 0.019, respectively). The level of tumor heterogeneity reduction (evaluated by texture feature) is higher in the NACT responders than in the nonresponders. The results suggested that changes in DCE-MRI features that reflect a reduction in tumor heterogeneity following NACT could provide early prediction of breast tumor response. The prediction was improved when the molecular subtype information was combined into the model.

Highlights

  • Neoadjuvant chemotherapy (NACT) is commonly used in treatment of locally advanced or large operable breast cancers with the aim of downstaging before surgery (Taghian et al, 2004; Kaufmann et al, 2007)

  • This result indicated that a high Jacobian value that represents a lower level of voxelwise shrink inside a tumor is associated with a failure of treatment

  • Radiomics features from longitudinal images and the changes in tumor heterogeneity were fused for the prediction

Read more

Summary

Introduction

Neoadjuvant chemotherapy (NACT) is commonly used in treatment of locally advanced or large operable breast cancers with the aim of downstaging before surgery (Taghian et al, 2004; Kaufmann et al, 2007). Radiomics features derived from the pretreatment MRI have been used for predicting response to NACT for breast cancer (Uematsu et al, 2010; Braman et al, 2017; Santamaría et al, 2017; Reig et al, 2020). Our previous study used DCE-MRI to identify and validate predictive imaging biomarkers for NACT using two datasets with different imaging protocols for training and testing (Fan et al, 2017).

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.